Patients entering the open-label dose optimization phase initiated treatment with MPH-LA @ mg/day ; up/down titrated to their optimal dose ( at which there was balance between control of symptoms and side effects ) of @ , @ , or @ mg/day in increments of @ mg/week by week @ or @ .